What question did this study set out to answer?

To evaluate how noninvasive imaging modalities can serve as effective biomarkers for assessing tumor vascularity, determining optimal drug dosing, and monitoring therapeutic response during anti-angiogenic drug development.

February 1, 2005JNCI Journal of the National Cancer InstituteOpen Access

Imaging Angiogenesis: Applications and Potential for Drug Development

View Full Paper

Ask AI

Bookmark

To evaluate how noninvasive imaging modalities can serve as effective biomarkers for assessing tumor vascularity, determining optimal drug dosing, and monitoring therapeutic response during anti-angiogenic drug development.
Reviewed noninvasive imaging modalities including positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and optical imaging.
Evaluated analytic techniques for deriving blood flow, blood volume, and semiquantitative or quantitative hemodynamic parameters from pharmacokinetic modeling.
Assessed method validity, measurement reproducibility, and correlations with pathologic indicators such as microvessel density and patient outcomes.
Imaging biomarkers provide rapid, noninvasive functional measurements of angiogenic vasculature, overcoming the dosing and response-assessment limitations inherent to cytostatic agents.
Quantitative hemodynamic parameters derived from pharmacokinetic modeling correlate with tumor microvessel density and histopathologic response, offering reliable endpoints for early-phase clinical trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review demonstrates the utility of vascular imaging biomarkers in cancer clinical trials, indicating their value for optimizing anti-angiogenic drug dosing and monitoring treatment response.

Cite This Study

Miller et al. (2005) studied this question.

synapsesocial.com/papers/6a08a9bd280cd4e998e8d6a7 https://doi.org/10.1093/jnci/dji023

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates the utility of vascular imaging biomarkers in cancer clinical trials, indicating their value for optimizing anti-angiogenic drug dosing and monitoring treatment response.

Imaging Angiogenesis: Applications and Potential for Drug Development

Key Points

Discussion

Implication

Cite This Study

Imaging Angiogenesis: Applications and Potential for Drug Development

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading